B-SDG rats exhibit the smallest thymus size
THP-1 human leukemia xenograft model in B-SDG rats and B-Rag2 KO rats
MIA PaCa-2 human pancreas cancer xenograft model in B-SDG rats and B-Rag2 KO rats
NCI-H460 human lung cancer xenograft model in B-SDG rats and B-Rag2 KO rats
Subcutaneous homograft tumor growth of NCI-H460 cells in B-SDG rats and B-Rag2 KO rats. Human lung cancer cell line H460 (2x107) were mixed with Matrigel and inoculated subcutaneously into B-SDG rats and B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, H460 cells were able to establish tumors in B-SDG rats and B-Rag2 KO rats, and the two strains of rats can be used for efficacy studies.
NCI-H1373 human lung cancer xenograft model in B-SDG rats and B-Rag2 KO rats
Subcutaneous homograft tumor growth of NCI-H1373 cells in B-SDG rats and B-Rag2 KO rats. Human lung cancer cell line NCI-H1373 (2x107) were mixed with Matrigel and inoculated subcutaneously into B-SDG rats and B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, NCI-H1373 cells were able to establish tumors in B-SDG rats and B-Rag2 KO rats, and the two strains of rats can be used for efficacy studies.
Subcutaneous homograft tumor growth of RT-112 cells in B-SDG rats and B-Rag2 KO rats. Human bladder cancer cell line RT-112 (1x107) were mixed with Matrigel and inoculated subcutaneously into B-SDG rats and B-Rag2 KO rats (n=5). (A)Tumor volume. (B) Body weight change. As shown in panel A, RT-112 cells were able to establish tumors in B-SDG rats and B-Rag2 KO rats, and the two strains of rats can be used for efficacy studies.
In vivo efficacy of cisplatin evaluated with B-SDG rats
Antitumor activity of cisplatin in B-SDG rats. (A) Cisplatin inhibited HCC1954 tumor growth in B-SDG rats. Human breast invasive ductal carcinoma cell line HCC1954 (2E7) were subcutaneously implanted into B-SDG rats (female, 9-week-old, n=6). The rats were grouped when tumor volume reached approximately 300-400 mm3, at which time they were treated with cisplatin with doses indicated in panel. (B) Body weight changes during treatment. As shown in panel A, cisplatin was efficacious in controlling tumor growth in B-SDG rats, demonstrating that B-SDG rats provide a powerful preclinical model for in vivo evaluation of chemotherapies. Values are expressed as mean ± SEM.
In vivo efficacy of cisplatin evaluated with B-SDG rats